XORTX Therapeutics (XRTX) EBITDA Margin (2023)

XORTX Therapeutics' (XRTX) quarterly EBITDA Margin came in at 140.09% in Q3 2023, down 40.09% on a QoQ basis from 100.0% in Q2 2023.

XORTX Therapeutics (XRTX) EBITDA Margin (2023) Analysis & Trends

XORTX Therapeutics (XRTX) has 1 years of EBITDA Margin data on file, last reported at 140.09% in Q3 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBITDA Margin (Qtr)
1	Vertex Pharmaceuticals	139.96 Bn	132.11 Bn	2.84 Bn	37.40%
2	Regeneron Pharmaceuticals	86.79 Bn	78.79 Bn	3.93 Bn	30.15%
3	Argenx Se	65.22 Bn	60.03 Bn	1.37 Bn	32.54%
4	Moderna	60.20 Bn	55.06 Bn	52.00 Mn	-562.07%
5	BeOne Medicines	42.19 Bn	37.09 Bn	1.53 Bn	19.06%
6	Alnylam Pharmaceuticals	31.43 Bn	28.12 Bn	992.69 Mn	17.93%
7	BioNTech SE	28.65 Bn	10.26 Bn	668.28 Mn	-35.57%
8	Insmed	27.48 Bn	26.32 Bn	358.27 Mn	-0.36%
9	Royalty Pharma	27.16 Bn	26.32 Bn	-	19.75%
10	XORTX Therapeutics	2.84 Mn	2.84 Mn	-	-

Download Data